The effect of anti-Parkinson drugs on catalepsy induced by  -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
D000547:Amantadine / Q000627:therapeutic use; D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001058:Apomorphine / Q000627:therapeutic use; D001545:Benserazide / Q000627:therapeutic use; D001590:Benztropine / Q000627:therapeutic use; D001923:Brain Chemistry / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced* / Q000188:drug therapy; D003913:Dextroamphetamine / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology*; D008774:Methylphenidate / Q000627:therapeutic use; D008781:Methyltyrosines; D051381:Rats; D012110:Reserpine; D012601:Scopolamine / Q000627:therapeutic use
D000978:Antiparkinson Agents; D006892:Hydroxydopamines; D008781:Methyltyrosines; D001590:Benztropine; D008774:Methylphenidate; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D012110:Reserpine; D000547:Amantadine; D000661:Amphetamine; D012601:Scopolamine; D001058:Apomorphine; D003913:Dextroamphetamine